Haystack Project Working With Lawmakers On Rare Disease Approval Legislation

By Maaisha Osman / October 28, 2024 at 9:00 AM
The rare disease advocacy group Haystack Project told Inside Health Policy that they are working with Senate and House lawmakers including the House Energy & Commerce Committee to develop new legislation to allow alternatives to randomized controlled trials (RCTs) for rare disease products. Haystack does not back existing legislation that would create a limited-term conditional approval pathway; instead, it’s arguing that FDA’s overarching “substantial evidence” standard should remain intact, but that action from Congress is needed to ensure alternative...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.